Intracameral moxifloxacin minimizes risk of endophthalmitis
- Posted on: Jun 19 2019
- Leave a response
This is the first prospective randomized clinical trial assessing the safety and efficacy of intracameral moxifloxacin for preventing post-cataract endophthalmitis.
Source: AAO
Posted in: Uncategorized